Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pharyngitis Treatment Market Size Changed, over the years?

In recent times, the market size for pharyngitis treatment has expanded continuously. It is projected to escalate from $2.27 billion in 2024 to approximately $2.37 billion in 2025, advancing at a compound annual growth rate (CAGR) of 4.5%. The expansion during the historic period is primarily due to a high number of recorded flu cases, an increased incidence of pharyngitis, raising awareness regarding pharyngitis, improved accessibility to healthcare facilities, and soaring personal disposable income.

How Much Will the Pharyngitis Treatment Market Be Worth in 2029?

The market size for pharyngitis treatment is set for robust expansion in the coming years, reaching a projected value of $2.99 billion by 2029, experiencing a compound annual growth rate of 6.0%. This predicted growth for the forecast period is due to several factors including the growing implementation of rapid point-of-care tests, increased demand for personalized medicine, the prevalence of antibiotic resistance, and a heightened focus on hand hygiene. Key trends projected for this forecast period encompass further advancements in research and development of pharyngitis therapies and the integration of digital health technologies and telehealth.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

Which is the Largest Company in the Pharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

What Are the Main Market Drivers in the Pharyngitis Treatment Industry?

With a surge in the transmission of strep throat, the pharyngitis treatment market is set to witness an upward trajectory in its growth. Strep throat is an infectious bacterial disease primarily concentrated in the tonsils and throat. Timely and effective adherence to antibiotic treatments can help lessen the symptoms, reduce the chances of complications, and diminish the possibility of passing the infection onto others. As per data released by the Centers for Disease Control and Prevention, a government agency based in the United States, annually, there are reported around 14,000 to 25,000 incidents of invasive Group A strep disease within the country. Furthermore, strep diseases result in about 5.2 million outpatient visits along with around 2.8 million antibiotic prescriptions every year. This surge in strep throat transmission is instrumental in propelling the pharyngitis treatment market. Pharyngitis Treatment Market Driver: The pharyngitis treatment market is set to grow due to an escalation in cases of influenza. Influenza, also known as the flu, is an infectious disease affecting the respiratory system and is caused by influenza viruses. Treatments for pharyngitis are largely administered to treat influenza, and these are instrumental in soothing symptoms, which primarily include inflammation or irritation, besides focusing on relieving allergies and preventing possible complications such as bronchitis and pneumonia. As per a report by the European Centre for Disease Prevention and Control (ECDC), a government agency based in Sweden, during the 2022/2023 influenza season within the EU/EEA, the weekly percentage of positive influenza specimens reached a high of 42% in the 51st week of 2022. Thereafter, the positivity rate stayed around 28% from the 5th to the 12th week of 2023. The increasing incidence of influenza is therefore boosting the growth of the pharyngitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

How Is the Pharyngitis Treatment Market Segments Structured?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

What Strategic Trends Are Transforming the Pharyngitis Treatment Market?

Leading enterprises within the pharyngitis treatment industry are concentrating their efforts on pioneering novel product solutions like oral monotherapy for improved patient adherence and to offer efficacious, accessible treatment options. Oral monotherapy involves usage of a singular pharmaceutical or medication orally ingested for the management of a particular disease or condition. The method solely includes one therapeutic agent instead of multiple treatments to accomplish the required therapeutic effect. For example, in December 2023, Swiss pharmaceutical firm Novartis AG received FDA endorsement for Fabhalta (iptacopan), marking it as the inaugural oral monotherapy for grown-up patients with paroxysmal nocturnal hemoglobinuria (PNH). This achievement, realized on [date], embodies a substantial progress by introducing a fresh treatment alternative that boosts hemoglobin quantities, thereby eliminating the necessity for blood transfusions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

This Report Delivers Insight On:

1. How big is the pharyngitis treatment market, and how is it changing globally?

2. Who are the major companies in the pharyngitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the pharyngitis treatment market right now?

4. Which products or customer segments are growing the most in the pharyngitis treatment market?

5. What factors are helping or slowing down the growth of the pharyngitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model